Suivi immunologique des patients traités par cellules CAR-T pour hémopathie maligne: recommandations du groupe CARTi et de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Majzner, 2019, Clinical lessons learned from the first leg of the CAR T cell journey, Nat Med, 25, 1341, 10.1038/s41591-019-0564-6

Du, 2020, Biomarkers in individualized management of chimeric antigen receptor T cell therapy, Biomark Res, 8, 13, 10.1186/s40364-020-00190-8

Hayden, 2019, An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on beh**alf of the chronic malignancies working party of EBMT, Curr Res Transl Med, 10.1016/j.retram.2019.05.002

Locke, 2019, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial, Lancet Oncol, 20, 31, 10.1016/S1470-2045(18)30864-7

Danylesko, 2019, Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia, Curr Res Transl Med, 68, 17, 10.1016/j.retram.2019.12.001

Vercellino, 2020, Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, Blood Adv, 4, 5607, 10.1182/bloodadvances.2020003001

Dean, 2020, High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma, Blood Adv, 4, 3268, 10.1182/bloodadvances.2020001900

Cheng, 2019, Understanding the mechanisms of resistance to CAR T-Cell therapy in malignancies, Front Oncol, 9, 1237, 10.3389/fonc.2019.01237

Fraietta, 2018, Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia, Nat Med, 24, 563, 10.1038/s41591-018-0010-1

Raje, 2019, Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma, N Engl J Med, 380, 1726, 10.1056/NEJMoa1817226

Cohen, 2019, B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma, J Clin Invest, 129, 2210, 10.1172/JCI126397

Finney, 2019, CD19 CAR T cell product and disease attributes predict leukemia remission durability, J Clin Invest, 129, 2123, 10.1172/JCI125423

Fraietta, 2016, Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia, Blood, 127, 1117, 10.1182/blood-2015-11-679134

Hirayama, 2019, The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells, Blood, 133, 1876, 10.1182/blood-2018-11-887067

Rossi, 2018, Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL, Blood, 132, 804, 10.1182/blood-2018-01-828343

Gardner, 2017, Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208

Schultz, 2020, Chimeric antigen receptor T Cell therapy for pediatric B-ALL: narrowing the gap between early and long-term outcomes, Front Immunol, 11, 1985, 10.3389/fimmu.2020.01985

Long, 2015, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nat Med, 21, 581, 10.1038/nm.3838

Kawalekar, 2016, Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells, Immunity, 44, 380, 10.1016/j.immuni.2016.01.021

Salter, 2018, Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function, Sci Signal, 11, 10.1126/scisignal.aat6753

Mueller, 2017, Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia, Blood, 130, 2317, 10.1182/blood-2017-06-786129

Deng, 2020, Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas, Nat Med, 26, 1878, 10.1038/s41591-020-1061-7

Yakoub-Agha, 2019, Management of cytokine release syndrome in adult and pediatric patients undergoing CAR-T cell therapy for hematological malignancies: Recommendation of the French Society of Bone Marrow and cellular Therapy (SFGM-TC), Bull Cancer, 106, S102, 10.1016/j.bulcan.2018.12.001

Hay, 2017, Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy, Blood, 130, 2295, 10.1182/blood-2017-06-793141

Brudno, 2019, Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management, Blood Rev, 34, 45, 10.1016/j.blre.2018.11.002

Wang, 2018, Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy, Biomark Res, 6, 4, 10.1186/s40364-018-0116-0

Parker, 2020, Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies, Cell, 183, 10.1016/j.cell.2020.08.022

Logue, 2020, Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma, Haematologica

Hill, 2018, Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy, Blood, 131, 121, 10.1182/blood-2017-07-793760

Park, 2018, Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-Cell acute lymphoblastic leukemia treated with chimeric antigen receptor T Cells, Clin Infect Dis, 67, 533, 10.1093/cid/ciy152

Hill, 2020, How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies, Blood, 136, 925, 10.1182/blood.2019004000

Jena, 2013, Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials, PLoS One, 8, e57838, 10.1371/journal.pone.0057838

Chen, 2020, Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy, JCI Insight, 5, 10.1172/jci.insight.134612

Hu, 2020, The chimeric antigen receptor detection toolkit, Front Immunol, 11, 1770, 10.3389/fimmu.2020.01770

Vogelstein, 1999, Digital PCR, Proc Natl Acad Sci U S A, 96, 9236, 10.1073/pnas.96.16.9236

Mika, 2020, Digital-droplet PCR for quantification of CD19-directed CAR T-Cells, Front Mol Biosci, 7, 84, 10.3389/fmolb.2020.00084

Wang, 2018, Establishment of a quantitative polymerase chain reaction assay for monitoring chimeric antigen receptor T Cells in peripheral blood, Transplant Proc, 50, 104, 10.1016/j.transproceed.2017.11.028

Fehse, 2020, Digital PCR assays for precise quantification of CD19-CAR-T cells after treatment with axicabtagene ciloleucel, Mol Ther Methods Clin Dev, 16, 172, 10.1016/j.omtm.2019.12.018

Lin, 2016, Application of droplet digital PCR for estimating vector copy number states in stem cell gene therapy, Hum Gene Ther Methods, 27, 197, 10.1089/hgtb.2016.059

Flower, 2000, Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-alpha and leptin, Cytokine, 12, 1712, 10.1006/cyto.2000.0764

Aldo, 2016, Simple plex: a novel multi-analyte, automated microfluidic immunoassay platform for the detection of human and mouse cytokines and chemokines, Am J Reprod Immunol, 75, 678, 10.1111/aji.12512

Tipton, 2016, How we harmonize HSCT clinical practices among the SFGM-TC centers, Bull Cancer, 103, S193, 10.1016/j.bulcan.2016.09.006

Yakoub-Agha, 2017, Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), Bull Cancer, 104, S43, 10.1016/j.bulcan.2017.10.017